Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease
US-2024360447-A1 · Oct 31, 2024 · US
US9593141B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593141-B2 |
| Application number | US-201214357020-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2012 |
| Priority date | Nov 9, 2011 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
Opening claim text (preview).
What is claimed is: 1. An RNA oligonucleotide comprising: a. a nucleotide sequence of formula 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′, wherein N 2 , N 4 , N 5 and N 7 are independently a purine; N 1 , N 3 , N 6 , N 8 , and N 9 are independently a pyrimidine; and b. a nucleotide sequence of 5′-GGAG-3′, wherein the sequence 5′-GGAG-3′ is linked to the 3′ of the sequence of formula 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′, wherein the sequence 5′-GGAG-3′ is single-stranded, wherein there are from 0 to 25 nucleotides between the 3′ end of 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′ and 5′ end of the sequence 5′-GGAG-3′, and wherein the RNA oligonucleotide is 18-100 nucleotides in length. 2. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a hairpin structure comprising a hairpin loop of at least 3 nucleotides and N 4 , N 5 , and N 6 are in the loop region of the hairpin. 3. The oligonucleotide of claim 2 , wherein the hairpin structure comprises a double-stranded stem of at least four nucleotide base pairs, wherein the stem is fully double-stranded. 4. The oligonucleotide of claim 3 , wherein the stem comprises at least one G-clamp:G or guanadinium-G-clamp:G base pair. 5. The oligonucleotide of claim 4 , the stem is terminated by a G:C, G:U, G-clamp:G or guanadinium-G-clamp:G base pair. 6. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises at least one modification selected from the group consisting of a sugar modification, a non-phosphodiester intersugar (or internucleoside) linkage, nucleobase modification, and ligand conjugation. 7. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a fluorescent reporter. 8. The oligonucleotide of claim 1 , wherein the 5′ end of the oligonucleotide is covalently linked to the 3′ end of the oligonucleotide. 9. The oligonucleotide of claim 1 , wherein N 1 and N 3 are independently selected purines and N 7 , N 8 , and N 9 are independently selected pyrimidines. 10. The oligonucleotide of claim 1 , wherein N 2 and N 4 are guanosine and N 5 is adenosine. 11. The oligonucleotide of claim 1 , wherein N 1 and N 5 are adenosine; N 3 is adenosine or uridine; N 2 and N 4 are guanosine; and N 6 , N 7 , N 8 , and N 9 are uridine. 12. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises the (SEQ ID NO: 16) 5′-GGGCAGAGAUUUUGCCCGGAG-3′ or (SEQ ID NO: 17) 5′-GGGGUAGUGAUUUUACCCUGGAG-3′. 13. The oligonucleotide of claim 1 , wherein N 1 , N 3 , and N 6 are uridine; N 2 , N 5 , and N 7 are adenosine; N 4 is guanosine; and N 8 and N 9 are cytosine. 14. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises the sequence (SEQ ID NO: 18) 5′-GGGGUCUAUGAUACCACCCCGGAG-3′. 15. A method for promoting miRNA processing of pri-miRNA to mature miRNA in a cell, wherein the miRNA is a let-7 family member, the method comprising contacting a cell with an isolated oligonucleotide of claim 1 .
Double-stranded nucleic acids or oligonucleotides · CPC title
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title
with ribosyl as saccharide radical · CPC title
Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT · CPC title
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.